Taxanes are chemotherapeutic drugs that are extensively used for a range of cancers, such as breast, ovarian, prostrate, and lung cancer, among others.
University of Alberta researchers have identified a predictive marker to screen patients that are being considered for taxane-based chemotherapy.
Elevated levels of this protein marker correlate with increased breast cancer patient survival after adjuvant-taxane treatment. In vitro experiments using siRNA to knock-down protein expression demonstrate that the marker is a critical effector molecule in the mechanism of action of taxane induced cytotoxicity.
Physicians will now be able to make more informed treatment decisions in regards to taxane usage based on an antibody-based assay to screen patient biopsy samples for the expression levels of the predictive marker. Further research is ongoing to validate this method utilizing samples from a large randomized controlled clinical trial.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
critical effector molecule
taxane induced cytotoxicity
taxane usage based
method utilizing samples
informed treatment decisions